Recent Updates
Recently added Catalysts
ACAD Positive Sentiment

Acadia Pharmaceuticals to Announce First Quarter 2026 Financial Results on May 6, 2026

Key Takeaway: Acadia Pharmaceuticals has announced it will report its first quarter 2026 financial results on May 6, 2026, after the U.S. markets close. The company will also host a conference call and webcast at 4:30 p.m. Eastern Time on the same day. This event will be accessible via Acadia's website and will be archived for later access.
Price reaction · baseline $21.76 (2026-04-15 close) · hit pre-market · 1 other ACAD headline(s) in the window, move may be shared
day 0 close · peak
-2.3%

Market Sentiment Analysis

POSITIVE FACTORS

  • Acadia Pharmaceuticals is set to report its financial results, indicating ongoing business activity.
  • The company continues to focus on innovative treatments for underserved neurological conditions.
  • The upcoming conference call provides transparency and engagement with investors.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+12%
120-day peak, hindsight
Typical move
5.6%
average across 7 past catalysts
Lead asset
Pimavanserin
Phase 2 · Agitation and Aggression in Alzheimer's Disease

Full Press Release Details

Company to host conference call and webcast on Wednesday, May 6, 2026, at 4:30 p.m. Eastern Time
SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will report first quarter 2026 financial results on Wednesday, May 6, 2026, after the close of the U.S. financial markets. Acadia’s management team will also host a conference call and webcast on May 6, 2026, at 4:30 p.m. Eastern Time.
The conference call will be available on Acadia’s website,acadia.comunder the investors section and will be archived there until August 15, 2026. The conference call may also be accessed by registering for the callhere. Once registered, participants will receive an email with the dial-in number and unique PIN number to use for accessing the call.
About Acadia Pharmaceuticals
Acadia is committed to turning scientific promise into meaningful innovation that makes the difference for underserved neurological and rare disease communities around the world. Our commercial portfolio includes the first and only FDA-approved treatments for Parkinson’s disease psychosis and Rett syndrome. We are developing the next wave of therapeutic advancements with a robust and diverse pipeline that includes mid- to late-stage programs in Alzheimer’s disease psychosis and Lewy body dementia psychosis, along with earlier-stage programs that address other underserved patient needs. At Acadia, we’re here to be their difference. For more information, visit us atacadia.comand follow us onLinkedInandX.

Frequently Asked Questions

When will Acadia report its Q1 2026 financial results?

Acadia Pharmaceuticals will report its Q1 2026 financial results on May 6, 2026.

What time is the conference call for Q1 2026 results?

The conference call will take place at 4:30 p.m. Eastern Time on May 6, 2026.

How can I access the conference call?

The conference call can be accessed via Acadia's website after registration.

Will the conference call be available later?

Yes, the conference call will be archived on Acadia's website until August 15, 2026.

Last updated: Apr 16, 2026